{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:26:50Z","timestamp":1767839210997,"version":"3.49.0"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T00:00:00Z","timestamp":1346889600000},"content-version":"vor","delay-in-days":1101,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p>Specialist physicians may have prescribing habits that are different from nonspecialist physicians. Little is known about the prescribing habits of physicians specializing in the treatment of obesity. An anonymous survey was given to the physician members of the American Society of Bariatric Physicians (ASBP). There was a 35% response rate (266 physicians) to the questionnaire that was represented nationally. Almost all prescribed medications and all of them recommended phentermine. The average maximal dose of phentermine was above that approved in the package insert, and these physicians disagreed with the National Institutes of Health (NIH) Obesity Treatment Guidelines. Phendimetrazine, metformin, and phentermine plus <jats:sc>l<\/jats:sc>\u20105\u2010hydroxytryptophan (5\u2010HTP) with carbidopa were all used more frequently than either orlistat or sibutramine. The combination of sibutramine and orlistat as well as 5\u2010HTP\/carbidopa were prescribed by 14 and 20%, respectively. As 5\u2010HTP\u2010carbidopa was a combination not previously reported for the treatment of obesity, a retrospective chart review was performed in a single obesity practice, which may not be representative. Twenty\u2010two subjects had a 16% weight loss with phentermine over 6 months and an additional 1% weight loss with the addition of 5\u2010HTP\/carbidopa for an additional 6 months. One subject who started on 5\u2010HTP\/carbidopa alone lost 24.4% of initial body weight over 6 months. This questionnaire revealed that 20% of the obesity specialists responding to the survey used phentermine plus of 5\u2010HTP\/carbidopa, an unreported combination. A controlled, randomized, clinical trial to evaluate the safety and efficacy of this combination in treating obesity should be considered.<\/jats:p>","DOI":"10.1038\/oby.2009.69","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T15:27:50Z","timestamp":1237476470000},"page":"1730-1735","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["How Physician Obesity Specialists Use Drugs to Treat Obesity"],"prefix":"10.1002","volume":"17","author":[{"given":"Ed J.","family":"Hendricks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank L.","family":"Greenway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,9,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-189308000-00001"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.20.6.0383"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.59.2.2"},{"key":"e_1_2_6_5_2","first-page":"1973","volume":"103","author":"National Institutes of Health: NIH Consensus Development Conference Statement, Health Implications of Obesity","year":"1985","journal-title":"Ann Int Med"},{"issue":"2","key":"e_1_2_6_6_2","first-page":"S51","article-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults\u2014the evidence report","volume":"6","author":"National Institutes of Health, National Heart, Blood and Lung Institute","year":"1998","journal-title":"Obes Res"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-7-200504050-00012"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012512"},{"key":"e_1_2_6_9_2","article-title":"Treatment of obesity with \u201ccombination\u201d pharmacotherapy","author":"Rothman RB","journal-title":"Am J Ther"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1467-789x.2001.00038.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2000.53"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.202.173"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1081\/ERC-200027356"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2004.09.006"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03327609"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2004.226"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.72"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.06.004"},{"key":"e_1_2_6_19_2","first-page":"271","article-title":"5\u2010Hydroxytryptophan: a clinically\u2010effective serotonin precursor","volume":"3","author":"Birdsall TC","year":"1998","journal-title":"Altern Med Rev"},{"key":"e_1_2_6_20_2","unstructured":"American Society of Bariatric Physicians. <http:www.asbp.orgsiterun_dataabout_asbpnews.phpq 770d63b79fe73fb00d7277f0b49285c0>. Accessed 11 November2008."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-2-199501150-00001"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-0220"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.044354"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-7-200410050-00014"}],"container-title":["Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Foby.2009.69","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Foby.2009.69","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/oby.2009.69","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T14:08:42Z","timestamp":1697465322000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1038\/oby.2009.69"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1038\/oby.2009.69"],"URL":"https:\/\/doi.org\/10.1038\/oby.2009.69","archive":["Portico"],"relation":{},"ISSN":["1930-7381","1930-739X"],"issn-type":[{"value":"1930-7381","type":"print"},{"value":"1930-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"2012-09-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}